PPWR Compliance for Pharma Importers Netherlands: The Readiness Playbook

PPWR compliance for pharma importers Netherlands means verifying that every packaging type you place on the Dutch market carries a manufacturer Declaration of Conformity, registering and reporting through Verpact, and being able to hand technical documentation to ILT within 10 days all under Regulation (EU) 2025/40, which applies from 12 August 2026.

Key takeaways

• No sector exemption. PPWR (Reg. (EU) 2025/40) applies directly from 12 August 2026 no national transposition, no pharma-wide carve-out.
• You collect, not create. Importers gather and retain the Declaration of Conformity per packaging type and produce Annex VII technical files on request within 10 days.
• Dutch layer stays. Register and report through Verpact above the 50,000 kg threshold; ILT and NVWA enforce.
• Exemptions are narrow. Immediate packaging (blisters, vials, ampoules) may escape recyclability rules; secondary cartons, leaflets and shipping boxes are fully in scope.
• Exempt ≠ free. Recyclability exemptions never remove EPR contributions you still pay eco-modulated fees.

What PPWR Compliance for Pharma Importers in the Netherlands Requires

Under PPWR compliance for pharma importers Netherlands, the importer is legally accountable for packaging it did not design Article 18 requires verifying the conformity assessment, collecting the Declaration of Conformity, and producing technical documentation on demand.

The Packaging and Packaging Waste Regulation Regulation (EU) 2025/40 entered into force on 11 February 2025 and applies from 12 August 2026. It replaces the 1994 Packaging Directive with a single, directly applicable rulebook across all 27 member states. For a pharmaceutical importer bringing packaged medicines into the Dutch market, Article 18 sets the core duties: confirm the manufacturer has run the conformity assessment, collect and keep the Declaration of Conformity for every packaging type, and hand technical documentation (prepared under Annex VII, Module A internal production control) to market surveillance authorities within 10 days of a request. In short, PPWR compliance for pharma importers Netherlands is an evidence obligation before it is a design one.

That accountability is the pressure point. You rarely control what your upstream manufacturer designs, yet you carry the legal exposure when non-conforming packaging reaches the Netherlands. PPWR compliance for pharma importers Netherlands therefore starts with supplier evidence, not with your own operation the Declaration of Conformity is issued by the packaging manufacturer, and your job is to request, verify and retain it at portfolio scale.

Understand PPWR Compliance Requirements and What They Mean for Your Business → Read the Blog

How PPWR Compliance for Pharma Importers Interacts with Verpact and ILT

In the Netherlands, PPWR layers on top of an existing extended producer responsibility system run through Verpact (formerly Afvalfonds Verpakkingen), with enforcement by ILT and the NVWA

PPWR keeps producer registers national. In the Netherlands, Verpact remains the collective EPR scheme you register and report through. Any company placing more than 50,000 kg of packaging on the Dutch market each year files a declaration and pays a waste-management contribution. From 12 August 2026, PPWR adds an EU-harmonised producer register, fees modulated by recyclability grade, and a mandatory authorised representative for producers not established in the Netherlands the point at which a foreign supplier can no longer simply self-register. This national layer is what makes PPWR compliance for pharma importers Netherlands distinct from the generic EU picture.

Enforcement sits with the Human Environment and Transport Inspectorate (ILT), alongside the NVWA, under the Wet milieubeheer. So PPWR compliance for pharma importers Netherlands is a two-layer exercise: satisfy the EU-level product requirements of Regulation (EU) 2025/40 while keeping your Dutch registration, annual declaration and reporting obligations current. Dutch enforcement has intensified since 2024, and ILT actively checks marketplace and distance-selling operators.

How Do PROs Fit Into PPWR Compliance? → Read the Blog

PPWR Pharma Packaging Exemptions: Where They Apply and Where They Don’t

PPWR gives pharma no blanket exemption; only immediate (product-contact) packaging and quality-preserving outer packaging are excluded from recyclability and recycled-content rules and never from EPR fees.

This is where pharma importers most often misread their exposure. Under Article 6, the immediate packaging of medicinal products blister packs, vials, ampoules, pre-filled syringes and the outer packaging strictly needed to preserve a medicine’s quality may be excluded from design-for-recyclability and recycled-content obligations (Art. 6(11)(a) and (d)). Secondary cartons, patient leaflets, grouped packaging and e-commerce shipping boxes receive no such relief and must comply in full.

Two caveats define real-world PPWR compliance for pharma importers Netherlands. First, the Commission’s April 2026 guidance reads the safety exemption narrowly it applies only where a recyclable alternative would genuinely compromise product stability, not merely where reformulation is costly. Second, exemptions from recyclability never remove EPR contributions: you still register, report and pay eco-modulated fees on every gram of packaging, and the carve-outs are under review to 2035. Layer on the operational rules a 50% empty-space cap on transport and e-commerce packaging, and a market ban on below-Grade-C packaging from 1 January 2030 and the exempt-versus-in-scope classification becomes a live, per-SKU decision.

Building a PPWR Compliance Workflow for Pharma Importers

A defensible workflow ties each SKU to its packaging types, Declarations of Conformity, Annex VII files, recyclability grades and Verpact reporting in one auditable record you can produce within 10 days

The operational challenge is data, not law. Pharma importers often run hundreds of SKUs, each with immediate, secondary and transport packaging sourced from different suppliers. To answer an ILT request inside the 10-day window, you need a packaging-level record mapping every SKU to its Declaration of Conformity, its technical file, its exemption status and its Verpact reporting line. Spreadsheets and shared inboxes rarely survive an audit at that scale, which is why PPWR compliance for pharma importers Netherlands is increasingly a systems decision rather than a paperwork one.

This is where a traceability platform earns its place in PPWR compliance for pharma importers Netherlands. The TraceX PPWR platform can centralise supplier documentation, flag missing or expiring Declarations of Conformity, classify packaging as exempt or in-scope, and hold the evidence in an audit-ready structure that maps to Verpact reporting. The goal is simple: turn a scramble into a query.

For pharma importers, PPWR is won or lost on documentation discipline. The teams that clear an ILT inspection are those that treated supplier Declarations of Conformity and Annex VII files as structured data from day one not those who assembled a folder after the 10-day clock started. The TraceX platform is built to keep that evidence continuously audit-ready and tied to each SKU

Manual Process vs. the TraceX Platform

Buyer Evaluation Checklist

Use this checklist to judge whether your PPWR compliance for pharma importers Netherlands is genuinely audit-ready or only looks that way on paper:

• Every packaging type mapped to a manufacturer Declaration of Conformity
• Annex VII technical documentation retained and retrievable within 10 days
• Immediate vs. secondary packaging classified for exemption eligibility, with rationale
• Verpact registration current; 50,000 kg threshold status confirmed
• Authorised representative appointed if not established in the Netherlands
• Recyclability grades logged against the 2030 below-Grade-C market-ban timeline
• Eco-modulated EPR fees reconciled against reported packaging volumes

Frequently Asked Questions